Show simple item record

dc.contributor.authorJaen-Moreno, M. J.
dc.contributor.authorGutiérrez Rojas, Luis 
dc.date.accessioned2021-04-23T10:18:13Z
dc.date.available2021-04-23T10:18:13Z
dc.date.issued2021-02-26
dc.identifier.citationJaen-Moreno MJ, Feu N, del Pozo GI, Gómez C, Carrión L, Chauca GM, Guler I, Montiel FJ, Sánchez MD, Alcalá JA, Gutierrez-Rojas L, Molina V, Bobes J, Balanzá-Martínez V, Ruiz-Rull C, Sarramea F (2021). Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking. European Psychiatry, 64(1), e22, 1–11 [https://doi.org/10.1192/j.eurpsy.2021.12]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/68074
dc.descriptionThis study receives founding by the Spanish Ministry of Economy, Industry, and Competitiveness, Instituto Carlos III (FIS PI16/00802).es_ES
dc.descriptionThe authors would like to thank M. Osuna, M. Ayora, J. Caballero, P. Zurita, N. Novoa, J. Álvarez, J. Fernández, J. Redondo, M.S. López, I. Caro, F. Valdivia, C. Sádaba, R. Luque, and L. Padilla for their assistance. We also thank the altruistic and generous participation of all the patients in that project.es_ES
dc.description.abstractBackground. This study has two main objectives: to describe the prevalence of undetected chronic obstructive pulmonary disease (COPD) in a clinical sample of smokers with severe mental illness (SMI), and to assess the value of the Tobacco Intensive Motivational Estimated Risk tool, which informs smokers of their respiratory risk and uses brief text messages to reinforce intervention. Method. A multicenter, randomized, open-label, and active-controlled clinical trial, with a 12-month follow-up. Outpatients with schizophrenia (SZ) and bipolar disorder were randomized either to the experimental group—studied by spirometry and informed of their calculated lung age and degree of obstruction (if any)—or to the active control group, who followed the 5 A’s intervention. Results. The study sample consisted of 160 patients (71.9% SZ), 78.1% of whom completed the 12-month follow-up. Of the patients who completed the spirometry test, 23.9% showed evidence of COPD (77.8% in moderate or severe stages). TIMER was associated with a significant reduction in tobacco use at week 12 and in the long term, 21.9% of patients reduced consumption and 14.6% at least halved it. At week 48, six patients (7.3%) allocated to the experimental group achieved the seven-day smoking abstinence confirmed by CO (primary outcome in terms of efficacy), compared to three (3.8%) in the control group. Conclusion. In this clinical pilot trial, one in four outpatients with an SMI who smoked had undiagnosed COPD. An intensive intervention tool favors the early detection of COPD and maintains its efficacy to quit smoking, compared with the standard 5 A’s intervention.es_ES
dc.description.sponsorshipSpanish Ministry of Economy, Industry, and Competitiveness, Instituto Carlos III FIS PI16/00802es_ES
dc.language.isoenges_ES
dc.publisherCambridge University Presses_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectBipolar disorderes_ES
dc.subjectCOPDes_ES
dc.subjectEarly detectiones_ES
dc.subjectSchizophrenia es_ES
dc.subjectSmokinges_ES
dc.titleChronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smokinges_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1192/j.eurpsy.2021.12
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones_ES


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España